Circulating tumour cells in non-metastatic breast cancer: a prospective study - 29/06/12
, Carolyn S Hall, PhD a, Ashutosh K Lodhi, MD a, Anirban Bhattacharyya, MD a, Amber E Anderson, BS a, Lianchun Xiao, MS c, Isabelle Bedrosian, MD a, Henry M Kuerer, ProfMD a, Savitri Krishnamurthy, ProfMD bSummary |
Background |
The identification of circulating tumour cells correlate with poor prognosis in metastatic breast cancer, but there are few data describing the importance of circulating tumour cells in patients with non-metastatic disease. Our aim was to establish if circulating tumour cells predicted worse outcome in patients with non-metastatic breast cancer.
Methods |
We prospectively collected data on circulating tumour cells at the time of definitive surgery from chemonaive patients with stage 1–3 breast cancer from February, 2005, to December, 2010. We deemed eligible all patients with operable breast cancer presenting at The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients were ineligible if they had bilateral breast cancer or any other malignancy within 5 years of the diagnosis of the present cancer. We measured circulating tumour cells with the CellSearch System (Veridex, Raritan, NJ). We correlated findings of circulating tumour cells with standard tumour characteristics, including tumour size and grade; oestrogen and progesterone receptor and human epidural growth factor receptor 2 (HER2) status; and axillary lymph node status with χ2 or Fisher exact tests. We assessed outcomes at a median follow-up of 35 months. Log-rank test and Cox regression analysis was applied to establish the association of circulating tumour cells with progression-free and overall survival.
Findings |
No patients reported adverse events or complications from blood collections. We identified one or more circulating tumour cells in 73 (24%) of 302 patients. Detection of one or more circulating tumour cells predicted both decreased progression-free survival (log-rank p=0·005; hazard ratio [HR] 4·62, 95% CI 1·79–11·9) and overall survival (log-rank p=0·01; HR 4·04, 1·28–12·8).
Interpretation |
The presence of one or more circulating tumour cells predicted early recurrence and decreased overall survival in chemonaive patients with non-metastatic breast cancer. These results suggest that assessment of circulating tumour cells might provide important prognostic information in these patients.
Funding |
Society of Surgical Oncology, Morgan Welch Inflammatory Breast Cancer Program, The University of Texas MD Anderson Cancer Center, and the State of Texas Rare and Aggressive Breast Cancer Research Program.
Le texte complet de cet article est disponible en PDF.Plan
Vol 13 - N° 7
P. 688-695 - juillet 2012 Retour au numéro
Article précédent
- Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
- Claus Rödel, Torsten Liersch, Heinz Becker, Rainer Fietkau, Werner Hohenberger, Torsten Hothorn, Ullrich Graeven, Dirk Arnold, Marga Lang-Welzenbach, Hans-Rudolf Raab, Heiko Sülberg, Christian Wittekind, Sergej Potapov, Ludger Staib, Clemens Hess, Karin Weigang-Köhler, Gerhard G Grabenbauer, Hans Hoffmanns, Fritz Lindemann, Anke Schlenska-Lange, Gunnar Folprecht, Rolf Sauer, on behalf of the German Rectal Cancer Study Group
- Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
- Ruth Pettengell, Bertrand Coiffier, Geetha Narayanan, Fernando Hurtado de Mendoza, Raghunadharao Digumarti, Henry Gomez, Pier Luigi Zinzani, Gary Schiller, David Rizzieri, Giles Boland, Paul Cernohous, Lixia Wang, Christine Kuepfer, Igor Gorbatchevsky, Jack W Singer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?